Research Paper | Pharmacology | E-ISSN No : 2454-9916 | Volume : 11 | Issue : 4 | April 2025

DOMINATION OF AI AND MACHINE LEARNING IN PHARMACEUTICAL BIOTECHNOLOGY AND PHARMACOGENOMICS

Yasmin Ansari[1], Pallavi Zode[1], Chaitanya Durge[1],

[1] Nagpur College of Pharmacy

ABSTRACT

The rapid advancement of Artificial Intelligence (AI) and Machine Learning (ML) is significantly transforming the landscape of pharmaceutical biotechnology and pharmacogenomics. These technologies are redefining how drugs are discovered, tested, and personalized for individual patients based on their genetic profiles. AI algorithms are now being used to identify potential drug candidates, predict molecular interactions, optimize clinical trials, and tailor therapies to enhance patient outcomes. In the realm of pharmacogenomics, ML models facilitate the interpretation of complex genomic data, enabling clinicians to anticipate drug responses and minimize adverse effects. While the benefits are substantial—ranging from faster innovation cycles to more precise medical interventions—the integration of AI also presents several challenges, including data quality issues, interpretability: of models, regulatory ambiguity, and ethical concerns around privacy and bias. This paper explores the current applications, tools, benefits, limitations, and future directions of AI and ML in pharmaceutical biotechnology and genomic medicine, emphasizing the potential of these technologies to drive a new era of personalized and predictive healthcare.

KEYWORDS: Artificial Intelligence (AI), Machine learning (ML), Pharmaceutical biotechnology, Pharmacogenomics, Algorithms, Genomic data

INTRODUCTION

Artificial Intelligence (AI) and Machine Learning (ML) have rapidly emerged as transformative forces in the domains of pharmaceutical biotechnology and pharmacogenomics. Traditionally, drug development and genetic research relied heavily on time-intensive, trial-and-error-based methods. However, the incorporation of AI and ML is fundamentally shifting this paradigm by introducing data-driven, predictive, and automated approaches that enhance the precision, efficiency, and speed of biomedical innovation.1(Topol., 2019)

In pharmaceutical biotechnology, AI is being employed to model complex biochemical systems, predict molecular interactions, design novel drug candidates, and optimize bioprocess engineering. These technologies assist researchers in deciphering vast amounts of multi-omics data (genomics, transcriptomics, proteomics, metabolomics), uncovering hidden patterns that would be difficult to detect using conventional methods.2(Chen., et al 2018)

In the context of pharmacogenomics, AI helps interpret individual genetic variations that influence drug response. By integrating genomic data with patient-specific clinical parameters, machine learning models can predict drug efficacy and adverse reactions, laying the foundation for personalized or precision medicine. This approach not only improves therapeutic outcomes but also minimizes the risk of harmful side effects, particularly in genetically diverse populations.3(Zhang., et al 2017)

The convergence of AI with biotechnology and genomics is catalyzing innovations across the drug development pipeline — from target identification and validation to clinical trial design, to post-market surveillance. Major pharmaceutical companies and research institutions have increasingly adopted AI-powered platforms to accelerate the discovery of biologics, cell and gene therapies, and mRNA-based vaccines.4(FDA., 2021)

Moreover, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have acknowledged the potential of AI in pharmaceutical contexts, prompting discussions around appropriate validation standards, ethical use, and data governance frameworks.5(Beam., et al 2018)

As the field matures, the integration of AI and ML into pharmaceutical and genomic research is not just augmenting existing workflows—it is redefining the possibilities of biomedical science itself.6(Dey., et al 2019)

Applications in Pharmaceutical Biotechnology

Artificial Intelligence (AI) and Machine Learning (ML) are now integral to pharmaceutical biotechnology, transforming how drugs are discovered, developed, and manufactured. These technologies enable the automation of complex biological analyses, uncover novel therapeutic targets, streamline production processes, and reduce the time and cost of biopharmaceutical development.

1. AI-Driven Drug Discovery:

AI algorithms are revolutionizing drug discovery by identifying potential drug candidates more rapidly and accurately than traditional methods. ML models can process extensive chemical libraries and predict the biological activity of compounds by

learning from existing datasets on molecular interactions, toxicity, and efficacy. This enables the early rejection of ineffective molecules and prioritization of promising leads. 7(Vamathevan., et al 2019)

Deep learning architectures, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), are used to model interactions between drugs and targets, such as proteins or receptors.

AI platforms like Atom Net and Deep Chem apply structure-based drug design principles to identify compounds that bind with high affinity to disease-related biomolecules.8 (Chen H., et al 2018)

2. Target Identification and Validation:

Identifying the right biological target is essential for successful therapeutic intervention. AI systems use data from genomics, transcriptomics, and proteomics to uncover disease-relevant targets. By integrating heterogeneous datasets, such as gene expression profiles and protein-protein interaction networks, AI helps uncover molecular signatures associated with disease states.9(Mak k., et al 2019)

Algorithms like support vector machines (SVM) and random forests are often used for classification and biomarker discovery.

Natural language processing (NLP) techniques can extract relevant biomedical knowledge from scientific literature to support hypothesis generation.

3. Predictive Toxicology and Drug Safety:-

Before clinical trials begin, assessing a drug's potential toxicity is crucial. AI models predict in vitro and in vivo toxicity using chemical structure, biological assay data, and gene expression responses.

Predictive toxicology platforms help minimize animal testing by forecasting adverse effects such as hepatotoxicity, cardiotoxicity, and neurotoxicity.

This improves patient safety and reduces attrition rates in the clinical pipeline.10 (Schwab., et al 2020)

4. Process Optimization in Biomanufacturing:

AI aids in optimizing upstream and downstream processes in the production of biologics, including therapeutic proteins, vaccines, and monoclonal antibodies. It can model and predict the influence of parameters such as pH, temperature, oxygen levels, and nutrient concentrations on cell growth and protein yield.

Reinforcement learning and neural network models are applied to fine-tune fermentation conditions in real-time.

Digital twins of bioreactors simulate production scenarios and guide process control, ensuring batch-to-batch consistency. (Ho D., et al 2020)

5. Quality Control and Predictive Maintenance:

AI facilitates real-time monitoring and quality assurance in biopharmaceutical manufacturing. Image recognition tools inspect bioproducts for contamination or structural integrity, while predictive analytics detect anomalies in equipment performance before failure occurs.

Machine learning enables predictive maintenance, reducing downtime and enhancing production efficiency.

AI-driven Process Analytical Technology (PAT) frameworks ensure regulatory compliance under Good Manufacturing Practices (GMP). (Chen H., et al 2018)

AI in Pharmacogenomics

Pharmacogenomics, the study of how genetic variation influences an individual's response to drugs, is a critical pillar of precision medicine. However, the integration of high-dimensional genomic data with clinical outcomes is a complex task. This is where Artificial Intelligence (AI) and Machine Learning (ML) have begun to play a transformative role. AI models are uniquely capable of analyzing vast, complex, and nonlinear datasets to identify patterns that underlie variability in drug response and toxicity across different genetic backgrounds. (Schwab., et al 2020)

1. Personalized Drug Response Prediction:

One of the most promising applications of AI in pharmacogenomics is the development of predictive models that correlate genetic variations—such as single nucleotide polymorphisms (SNPs)—with drug efficacy and adverse reactions. Machine learning techniques like logistic regression, support vector machines (SVMs), and ensemble methods can be trained on genomic and phenotypic data to forecast how a particular patient will respond to a specific treatment. .(Mak k., et al 2019)

These models help clinicians choose optimal drugs and doses tailored to a patient's genetic profile.

This is particularly useful in fields such as oncology, psychiatry, and cardiology, where drug response is highly individualized.

2. Identification of Pharmacogenomic Biomarkers:

AI algorithms can uncover genetic biomarkers that influence drug metabolism, efficacy, or risk of adverse effects. By integrating data from genome-wide association studies (GWAS), transcriptomics, and epigenomics, AI enables the identification of previously unrecognized gene-drug interactions.

Deep learning approaches are especially adept at identifying complex relationships in nonlinear gene networks.

These biomarkers can be used to stratify patients into treatment groups, improving the success rate of clinical trials. (Paul,. et al, 2021)

3. Optimization of Polygenic Risk Scores (PRS):

Traditional polygenic risk scores, which aggregate the effects

of multiple genetic variants, often oversimplify gene-drug relationships. AI allows for more sophisticated models that incorporate gene-gene and gene-environment interactions, leading to more accurate predictions of drug response.

Neural networks and decision trees can model complex, multi-layered interactions between genetic variants and clinical variables.

This supports more refined therapeutic stratification in populations with diverse genetic backgrounds.(Ramesh., et al 2022)

4. Clinical Decision Support Systems (CDSS):
AI-powered CDSS platforms are being developed to assist healthcare providers in interpreting pharmacogenomic data at the point of care. These systems analyze patient genomic profiles and recommend drug choices based on established gene-drug interaction databases and machine learning inference models.

Integration with Electronic Health Records (EHRs) enables real-time, automated alerts for potential drug-gene interactions. (Ekins., et al 2019)

This leads to safer prescribing practices and a reduction in trial-and-error treatment approaches.

5. Integration with Multi-Omics and Real-World Data:
AI excels at integrating pharmacogenomic data with other layers of biological and clinical data, such as proteomics, metabolomics, and patient lifestyle information. This holistic analysis enhances the understanding of how genetic factors interact with external influences to impact drug response.

For instance, reinforcement learning models can incorporate feedback from treatment outcomes to continuously refine predictive accuracy.

Such systems support a more dynamic and adaptive form of personalized medicine. (Topol., et al 2019)

Advantages of AI and ML in Pharmaceutical Biotechnology and Pharmacogenomics
The integration of Artificial Intelligence (AI) and Machine Learning (ML) into pharmaceutical and genomic sciences has introduced a paradigm shift in both research and clinical practice. These technologies offer numerous advantages that enhance the efficiency, precision, and personalization of drug development and therapeutic interventions. (Hinton., et al 2015)

1. Accelerated Drug Discovery and Development:
AI algorithms can process and analyze massive datasets at unprecedented speeds, significantly shortening the timeline of drug discovery. Traditional drug development, which often spans over a decade, can be expedited through AI-based virtual screening, molecular modeling, and compound optimization.

AI-driven tools can identify lead compounds, predict biological targets, and simulate drug-receptor interactions faster than conventional laboratory methods.

This results in reduced research costs and faster progression to clinical testing.(Jumper., et al 2021)

2. Enhanced Precision and Personalization:
Machine learning models enable the customization of treatment plans based on individual genetic profiles, environmental exposures, and lifestyle factors. In pharmacogenomics, this means drugs can be tailored to the unique genetic makeup of a patient, improving therapeutic efficacy and minimizing adverse drug reactions.

AI facilitates the development of personalized medicine by integrating multi-omics data and clinical variables.

It ensures the right drug is given to the right patient at the right dose.(Wu Z., et al 2018)

3. Improved Prediction of Drug Safety and Efficacy:
Predictive models built using ML algorithms can forecast drug toxicity and effectiveness before clinical trials begin. These insights help researchers prioritize the safest and most promising drug candidates early in the pipeline.

AI reduces the likelihood of late-stage clinical trial failures due to unforeseen side effects.

It enhances patient safety and increases the success rate of new therapies.(Devlin., et al 2019)

4. Integration and Interpretation of Complex Datasets:
AI excels at handling the complexity and volume of biological data generated in modern life sciences. Genomic sequencing, proteomic analysis, and electronic health records all produce massive datasets that require advanced computational tools for interpretation.

AI tools can reveal previously hidden associations between genes, diseases, and therapeutic responses.

This integrative approach improves the understanding of disease mechanisms and drug interactions.

5. Automation of Repetitive and Complex Tasks:
In laboratory settings and clinical data analysis, AI systems can automate tasks such as image analysis, data entry, and literature review. This frees up human researchers to focus on higher-level decision-making and hypothesis generation.

Natural Language Processing (NLP) can rapidly analyze scientific literature to extract relevant findings.

Automated platforms reduce human error and increase overall productivity.(Broad Institute 2020)

6. Cost Reduction and Resource Optimization:
AI significantly lowers the financial burden of pharmaceutical

R&D by reducing the need for extensive experimental trials and by optimizing resource allocation. Companies can prioritize high-potential drug candidates and design smarter clinical trials with adaptive protocols.

This is particularly valuable in rare diseases and niche therapeutic areas where patient populations are small and resources are limited.(H2o ai., 2022)

Key Tools and Platforms in AI and ML for Pharma and Genomics

To fully harness the power of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical and genomic research, a range of specialized tools and platforms has been developed. These tools enable efficient data processing, pattern recognition, predictive modeling, and decision-making across different stages of drug development and personalized medicine.

1. TensorFlow and PyTorch:

These are two of the most widely used open-source machine learning frameworks.

TensorFlow, developed by Google, provides robust capabilities for neural network construction, deep learning, and deployment at scale. It's highly favored for modeling biological systems, disease classification, and compound screening.

PyTorch, created by Facebook's AI Research Lab, is widely used in academia for its dynamic computational graph and ease of experimentation. It is popular in genomics for sequence analysis and gene expression prediction.(Obermeyer., et al 2016)

2. DeepChem:

DeepChem is a domain-specific open-source library designed for AI applications in drug discovery, bioinformatics, and quantum chemistry.

It supports tasks such as molecular property prediction, protein-ligand docking, and virtual screening.

DeepChem integrates well with TensorFlow and Scikit-learn, making it ideal for researchers building customized pipelines in pharmaceutical biotechnology.

3. IBM Watson for Drug Discovery:

IBM Watson uses natural language processing and deep learning to sift through massive volumes of biomedical literature, clinical trial data, and molecular databases.

Watson can identify novel drug-target interactions, suggest repurposing opportunities, and generate hypotheses.

It enables biopharma companies to shorten discovery timelines by identifying connections not obvious to human researchers. (Goodman 2017)

4. BioBERT and SciSpacy:

BioBERT (Bidirectional Encoder Representations from Transformers for Biomedical Text Mining) is an AI model trained specifically on biomedical literature to extract insights from research papers, clinical notes, and databases.

SciSpacy is a Python package tailored for scientific and biomedical natural language processing (NLP). It helps in entity recognition, relation extraction, and concept linking—important for mapping gene-drug interactions. (Weins 2019)

5. GATK (Genome Analysis Toolkit):

Developed by the Broad Institute, GATK is a widely used toolkit for variant discovery in genomic data.

While GATK itself is not AI, recent versions integrate ML-based variant calling algorithms to improve accuracy in identifying SNPs and indels from sequencing data.

It's essential in pharmacogenomics for identifying polymorphisms that influence drug response. (Panch 2019)

Challenges and Limitations of AI and ML in Pharma and Genomics

Despite the transformative potential of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical and genomic sciences, several challenges and limitations hinder their widespread application. These issues span technical, regulatory, ethical, and operational domains, and need to be addressed to ensure responsible and effective deployment of AI technologies in life sciences.

1. a. Data Quality and Availability:

High-quality, annotated, and diverse datasets are essential for training reliable AI models. However, in the pharmaceutical and genomic domains, data are often:

Fragmented across different systems and institutions (Chen, 2018)

Limited in size for rare diseases or new drug classes Prone to noise, missing values, or biased representation Insufficient or biased training data can lead to inaccurate predictions and reduced generalizability, especially in genetically diverse populations.

2. Lack of Interpretability ("Black Box" Problem):

Many ML models—especially deep learning networks—operate as "black boxes," producing accurate predictions without offering explanations for their decisions.

This lack of transparency is problematic in medicine, where clinicians need clear rationales for therapeutic recommendations.

Without interpretability, AI tools face resistance from regulators and practitioners who demand accountability in clinical decision-making.(Jumper2021)

3. Regulatory and Legal Uncertainty:
AI systems in healthcare and drug development operate in a complex legal environment where regulatory guidelines are still evolving.

There is ambiguity regarding the approval process for AI-driven diagnostic or therapeutic tools by authorities such as the FDA or EMA.

Questions around liability—especially in the case of incorrect predictions or adverse outcomes—remain unresolved.

4. Ethical and Privacy Concerns:
The use of AI in genomics involves sensitive personal data, raising significant ethical concerns related to:

Data privacy and the risk of re-identification from genomic information

Consent management for secondary use of genetic data

Algorithmic bias that could disproportionately affect marginalized or underrepresented populations

Ethical frameworks and robust governance mechanisms are essential to ensure that AI applications are fair, secure, and respectful of individual rights.

Future Directions of AI and ML in Pharmaceutical Biotechnology and Pharmacogenomics
As Artificial Intelligence (AI) and Machine Learning (ML) continue to evolve, their future role in pharmaceutical biotechnology and pharmacogenomics is set to be even more transformative. These technologies are poised to not only accelerate scientific discovery but also redefine how we approach drug design, personalized treatment, and genomic medicine.(Rajpurkar 2022)

1. Integration of Multi-Omics Data for Holistic Insights
Future applications of AI will increasingly focus on integrating diverse biological data types—genomics, transcriptomics, proteomics, metabolomics, and epigenomics—into unified analytical frameworks.

This multi-omics integration will provide a more comprehensive understanding of disease mechanisms and therapeutic targets.

AI will help decode complex biological networks, offering precise models for disease prediction and drug response.

2. AI-Driven Personalized Therapeutics
The shift from "one-size-fits-all" therapies to truly individualized treatments will be powered by AI models trained on genetic, phenotypic, and lifestyle data.

In pharmacogenomics, AI will enhance the design of adaptive treatment regimens, minimizing adverse drug reactions and maximizing efficacy.

Personalized AI platforms will predict individual patient responses and recommend optimized therapies based on real-time data.

3. Generative AI for De Novo Drug Design
The future of drug discovery will see the widespread use of generative AI models—like generative adversarial networks (GANs) and reinforcement learning—for designing entirely new molecular structures.

These models can propose novel compounds with high binding affinity, favorable pharmacokinetics, and low toxicity profiles.

The approach will significantly reduce the cost and time associated with traditional medicinal chemistry.

4. Expansion of AI in Clinical Trial Design and Monitoring
AI will enable more efficient, adaptive clinical trials by:
Identifying ideal patient cohorts using predictive analytics. Automating patient monitoring through wearable sensors and natural language processing, Reducing attrition rates through better compliance monitoring and early risk prediction, This evolution will make clinical trials more inclusive, data-driven, and patient-centered.

5. Edge AI and Real-Time Genomic Analysis
With the growth of portable sequencing technologies, edge computing (AI processing at or near the data source) will allow genomic data to be analyzed in real-time at the point of care.
This will enhance rapid diagnostics, especially in low-resource or emergency settings.

AI will support on-site decision-making for genomic surveillance, precision treatments, and infection control.(Beam 2018)

CONCLUSION
Artificial Intelligence (AI) and Machine Learning (ML) are no longer speculative tools in pharmaceutical biotechnology and pharmacogenomics—they have become foundational to scientific innovation and healthcare transformation. From accelerating drug discovery and optimizing clinical trials to enabling truly personalized medicine based on genomic profiles, AI and ML are revolutionizing every stage of the biomedical pipeline.

These technologies have demonstrated significant advantages: improved accuracy, reduced costs, faster decision-making, and deeper biological insights. Tools such as AlphaFold, DeepChem, and IBM Watson have already begun reshaping the research and development paradigm, making previously intractable problems solvable. At the same time, challenges like data privacy, interpretability, algorithmic bias, and regulatory uncertainty must be carefully navigated to ensure ethical and effective implementation.

Looking ahead, the integration of multi-omics data, explainable AI, and real-time genomic analytics promises to push the boundaries of what is medically and scientifically possible.

With continued interdisciplinary collaboration and robust governance frameworks, AI and ML are poised to usher in a new era of precision biotechnology—where therapies are tailored, discoveries are accelerated, and healthcare is transformed

REFERENCES

6. Topol, E. J. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.
7. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
8. Zhang, L., Tan, J., Han, D., & Zhu, H. (2017). From machine learning to deep learning: Progress in machine intelligence for rational drug discovery. Drug Discovery Today, 22(11), 1680–1685. https://doi.org/10.1016/j.drudis.2017.08.010
9. FDA. (2021). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. https://www.fda.gov/media/145022/download
10. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
11. Dey, D., Slomka, P. J., Leeson, P., Comaniciu, D., & Shrestha, S. (2019). Artificial Intelligence in Cardiovascular Imaging: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73(11), 1317–1335. https://doi.org/10.1016/j.jacc.2018.12.054
12. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
13. Chen, H., Engkvist, O., Wang, Y., et al. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
14. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
15. Schwab, M., et al. (2020). Predictive analytics and AI in manufacturing of biologics. Biotechnology Advances, 44, 107620. https://doi.org/10.1016/j.biotechadv.2020.107620
16. Ho, D., et al. (2020). Artificial intelligence in healthcare and biopharmaceuticals. Nature Biomedical Engineering, 4(10), 865–866. https://doi.org/10.1038/s41551-020-00660-0
17. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
18. Chen, H., Engkvist, O., Wang, Y., et al. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
19. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
20. Schwab, M., et al. (2020). Predictive analytics and AI in manufacturing of biologics. Biotechnology Advances, 44, 107620. https://doi.org/10.1016/j.biotechadv.2020.107620
21. Ho, D., et al. (2020). Artificial intelligence in healthcare and biopharmaceuticals. Nature Biomedical Engineering, 4(10), 865–866. https://doi.org/10.1038/s41551-020-00660-0
22. Paul, D., Sanap, G., Shenoy, S., et al. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
23. Ramesh, A., & Yu, M. K. (2022). Machine learning for personalized medicine. Nature Medicine, 28, 649–660. https://doi.org/10.1038/s41591-022-01718-y
24. Ekins, S., Puhl, A. C., Zorn, K. M., et al. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 18(5), 435–441. https://doi.org/10.1038/s41563-019-0338-z
25. Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.
26. Hinton, G. E., et al. (2015). Deep learning in healthcare: Opportunities and challenges. Nature, 526(7573), 436–444. https://doi.org/10.1038/nature14539
27. Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
28. Wu, Z., Ramsundar, B., et al. (2018). MoleculeNet: A benchmark for molecular machine learning. Chemical Science, 9(2), 513–530. https://doi.org/10.1039/C7SC02664A
29. Devlin, J., Chang, M. W., et al. (2019). BERT: Pre-training of deep bidirectional transformers for language understanding. Proceedings of NAACL-HLT, 4171–4186. https://doi.org/10.18653/v1/N19-1423
30. Broad Institute. (2020). GATK Best Practices. https://gatk.broadinstitute.org
31. H2O.ai Documentation. (2022). Machine Learning for Healthcare and Life Sciences. https://docs.h2o.ai/
32. Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.
33. Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future — Big data, machine learning, and clinical medicine. New England Journal of Medicine, 375(13), 1216–1219. https://doi.org/10.1056/NEJMp1606181
34. Goodman, B., & Flaxman, S. (2017). European Union regulations on algorithmic decision-making and a "right to explanation". AI Magazine, 38(3), 50–57. https://doi.org/10.1609/aimag.v38i3.2741
35. Wiens, J., Saria, S., et al. (2019). Do no harm: A roadmap for responsible machine learning in health care. Nature Medicine, 25(9), 1337–1340. https://doi.org/10.1038/s41591-019-0548-6
36. Panch, T., Mattie, H., & Celi, L. A. (2019). The "inconvenient truth" about AI in healthcare. npj Digital Medicine, 2, 77. https://doi.org/10.1038/s41746-019-0155-4
37. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
38. Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
39. Rajpurkar, P., et al. (2022). AI in health and medicine. Nature Biomedical Engineering, 6, 1–17. https://doi.org/10.1038/s41551-021-00806-2
40. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
41. Zhou, L., Pan, S. J., & Wang, F. (2021). Explainable artificial intelligence for healthcare: A survey. Nature Machine Intelligence, 3, 997–1006. https://doi.org/10.1038/s42256-021-00432-0
42. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
43. Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
44. Rajpurkar, P., et al. (2022). AI in health and medicine. Nature

Biomedical Engineering, 6, 1–17. https://doi.org/10.1038/s41551-021-00806-2

45. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391